Thar Pharmaceuticals, which is developing novel oral therapies for chronic pain utilizing the 505(b)(2) pathway, withdrew its plans for an initial public offering on Wednesday. It originally filed in August 2016 with a proposed deal size of $50 million. ...read more
Axsome Therapeutics, which is developing novel therapies for pain and CNS disorders utilizing the 505(b)(2) pathway, raised $51 million on Thursday by offering 5.67 million shares at $9. At $9 per share, the biotech went public at a market cap of $180...read more
In a week that could see ten IPOs, only one is a biotech. Next week, there are profitable, cash-flow positive companies; there are tech companies ranging from payment...read more
Going to great pains: Grünenthal acquires Thar Pharmaceuticals, which pulls $50 million IPO
Thar Pharmaceuticals, which is developing novel oral therapies for chronic pain utilizing the 505(b)(2) pathway, withdrew its plans for an initial public offering on Wednesday. It originally filed in August 2016 with a proposed deal size of $50 million. ...read more
US IPO Weekly Recap: Payments unicorn Square gains 43% after slashing price
All five IPOs priced at the low end or below the range this week but finished Friday with a positive return. ...read more
Axsome Therapeutics prices IPO below the range at $9; finishes Thursday down 3%
Axsome Therapeutics, which is developing novel therapies for pain and CNS disorders utilizing the 505(b)(2) pathway, raised $51 million on Thursday by offering 5.67 million shares at $9. At $9 per share, the biotech went public at a market cap of $180...read more
Week ahead: Ten deals set to raise $1.5 billion
In a week that could see ten IPOs, only one is a biotech. Next week, there are profitable, cash-flow positive companies; there are tech companies ranging from payment...read more